Der allererste Cannabis Wert in Kanada!

... muss ich sagen, dass ich absolut zufrieden bin. Werde mir Abends noch mehr Zeit nehmen zum genauen Zerlegen. Es stecken nach wie vor viele Vorschusslorbeeren im Kurs, die nun abverkauft werden. Angesichts der boomende Branche, der sehr guten Aussichten und auch dem massiven Investment von Canopy in Research und Optimierung, fände ich den eingepriesenen Vorschuss aber eigentlich komplett nachvollziehbar. Kennt jemand die aktuelle Shortseller-Rate? Vermutlich wird es nun wieder seitwärts um 8€/8,50€ gehen.

Der nächste Schub wird wohl erst mit der endgültig beschlossenen Legalisierung in Kanada kommen - bis dann die ersten Zahlen kommen, in denen sie sich das auch in den Q-berichten niederschlägt, brauchen wir sicher noch Geduld.  

Na ich hoffe doch, dass es jetzt langsam aber dafür sicher in kleinen Schritten weiter Richtung Norden geht. Canopy scheint für die Zukunft in Kanada, Australien und Deutschland ja gut aufgestellt zu sein.. Bin sehr gespannt was noch so alles passiert. In Kandada kann man ja jetz unter WEED traden XD

http://www.newswire.ca/news-releases/...ancial-results-613685223.html

Ich hab sogar schon Optionsscheine entdeckt, aber hab davon leider noch 0 Plan

http://www.onvista.de/zertifikate/suche/...UE=CA1380351009&STEP=2

 

It looks like Bruce has alluded to that upside in q4 revs correcting back for the inventory:
"Added Linton, "the recent release of our first wave of new genetics and Tweed Farms product resulted in one million dollars of store sales in a single day, on February 1. That is a major milestone for Canopy. Two years ago, we had our first million dollar quarter, a year ago we had our first million dollar month, and now we have had our first million dollar day. It's definitely trending well."  

https://news.lift.co/canadian-cannabis-goes-international/  

• AusCann’s first harvest in Chile on track for April 2017
• Eight different strains are being grown providing a range of chemical entities/ chemotypes to be used in trial formulations
• Product intended to be sold to third parties for use in a range of clinical trials later this year
• Successful trials will result in product registration driving demand and subsequent commercial sales  

https://markets.ft.com/data/equities/tearsheet/forecasts?s=WEED:TOR  

23 FEBRUARY 2017 GOVERNMENT TO FACILITATE FASTER ACCESS TO MEDICAL CANNABIS • AusCann welcomes Federal Government’s move to facilitate faster access to medical cannabis for patients • Government to expedite the authorisation process for the controlled importation by approved providers to enable patients to more rapidly access the medication • AusCann intends to import high quality cannabis medicines from its partner Canopy Corporation, one of the world’s largest medicinal cannabis companies, and following this announcement, its process for importing has become more streamlined. • The news propels AusCann’s strategy to deliver high quality, cost effective medicinal cannabis treatments to Australian patients AusCann Group Holdings Ltd (ASX:AC8 or ‘the Company’) is pleased to provide an update to the market on the regulatory developments that will drive forward its strategy to deliver high quality, cost effective medicinal cannabis treatments to Australian patients. The Government has announced it would facilitate faster access to medicinal cannabis for patients in Australia by authorising controlled importation by approved suppliers from international sources. Prior to today’s announcement, AusCann were required to have medical practitioners pre-authorised for a particular medicine, whereas now, the Company is able to expedite its application to become an approved supplier for the import for medical cannabis products. This will allow AusCann to import product ahead of time to meet demand from authorised prescribers and be in a position to more quickly provide patient access. This will significantly accelerate AusCann’s timeline in being to supply Australian patients. The medication imported will need to be stored in a safe and secure facility that meets the requirements of the Office of Drug Control and relevant state government requirements. The Government expects that within 8 weeks, Australia will have a store of imported medicinal cannabis products to be able to rapidly supply to patients, while they work to continue to establish the domestic cultivation and manufacture scheme. AusCann intends to establish a growing facility in Australia to eventually supply Australian patients with Australian grown and manufactured medicines. However, until domestic approvals are received, AusCann’s medicinal products will be imported from its partner Canopy Growth Corporation that is globally recognised as one of the leaders in medicinal cannabis. Elaine Darby, Managing Director, AusCann commented: “We welcome the decision by the Government to accelerate patient access to medicinal cannabis products. It is encouraging that they have been listening to patients and doctors and acting on their concerns. As more doctors seek to become authorised prescribers of the medication, AusCann are well placed among the medical community to be the supplier of choice for doctors and patients. Moreover, this move by the Government clearly signals their commitment to bring this medication to patients, Australia-wide.” ASX RELEASE AusCann Group Holdings Ltd ACN: 008 095 207 http://www.auscann.com.au/ Email: info@auscann.com.au Phone: +61 (8) 9561 8834 Registered Office: 85 Carabooda Road, Carabooda, Western Australia, 6033 For more information please contact AusCann Elaine Darby Managing Director Elaine.darby@auscann.com.au +61 8 9561 8834 For Investment Enquires Stewart Washer Stewart.washer@auscann.com.au +61 418 288 212 For Media Enquiries Caroline Zielinski Media & Capital Partners Caroline.zielinski@mcpartners.com.au +61 400 172 145 ABOUT AUSCANN GROUP AusCann is an Australian based company that was incorporated in September 2014 with the aim of producing and providing high quality, economical and clinically validated cannabis medicines to patients. It is bringing together leading expertise and operations across all aspects of the medical cannabis value chain, beginning with cultivation and production, through to manufacture and distribution of products and has built a strong team of experts and partners with international connections. Partners includes TSX listed Canopy Growth Corporations the largest producer of medicinal cannabis globally and DayaCann, the only licensed medicinal cannabis grower in Chile.  

http://www.fool.com.au/2017/03/06/...t-ipos-which-smashed-the-market/  

in Kanada ?
Weiß das jemand von euch genau ?  

https://www.bloomberg.com/quote/AC8:AU  

Voraussichtlich Mitte-Ende April , könnte aber auch Juni werden..

http://dankr.ca/news/...ation-running-no-later-6-months-next-election  

http://dankr.ca/news/...ation-running-no-later-6-months-next-election  

... da werde ich mir wohl keine Freunde machen, wenn ich heute mal absolut dagegen halte.....

Weed´s kraftloser Hilfeschrei......" wir wussten es nicht, bitte vertraut uns,... alles war >vor unserer Zeit >..... Leute Leute,........ wie blauäugig muss/darf man heute bei einer Firmenübernahme sein?

Ich sag nur "von Gier getrieben" !

Händeringend....versucht Canopy nun einer möglicherweise angemeldeten "Sammelklage" ehemaliger Mettrum Kunden "mit aller Entschlossenheit entgegenzuwirken". ...

Quelle:http://www.stockwatch.com/News/...450032&symbol=WEED&region=C

sry,...aber soviel Dummheit/Gier...., oder sollte man Unfähigkeit sagen?,... muss man / sollte man als Anleger mittragen? Abgesehen davon halte ich Canopy auf aktuellem Niveau für absolut überwebertet.... n.m.subjektive Meinung...

möglicherweise sind es heute bereits wieder Kaufkurse,...persönlich meine ich, darf man derzeit ruhig noch an der Seitenlinie bleiben...

Kurse um C§10,00 könnten ggf. noch kommen......

aktuell scheint es so, dass die Unterstützung bei C$11,92 eine ernstzunehmende Hürde darstellt und der Support bei C$10,27 immer wichtiger wird.... darunte wird es wirklich ärgerlich und Kurse in de Range von C$8-C$9 könnten durchaus auf dem Kurszettel erscheinen.....

Source:http://www.stockta.com/cgi-bin/...=WEED.C&cobrand=&mode=stock


mfG
Chinasky

 

Super Schachzug war das. Die Lizenzen die Canopy da abgestaubt hat sind Gold wert..und die Mettrumkunden ordern offensichtlich weiterhin XD Immerhin ist ja unter Canopy auch jetzt sichergestellt, das die Produkte vom Labor getestet sind. Im Übrigen hat dazu ja auch schon die Behörde mitgeteilt, das es sich bei dem Verwendetet Pestizid um das gleiche handelt was auch bei Obst verwendet wird....

http://www.hc-sc.gc.ca/dhp-mps/marihuana/info/...e/pesticides-eng.php

Davon Abgesehen betraf der Rückruf Organigram und Mettrum. Da Canopy ja Mettrum übernommen hat und auch sofort danach bei Mettrum "aufgeräumte", würde ich mal sagen: Alles richtig gemacht XD

An Open Letter from Bruce Linton Updating on Mettrum Transition to New Management and Implementation of Canopy Growth Operational Procedures SMITHS FALLS, ON, Feb. 23, 2017...https://cdn.shopify.com/s/files/1/0994/1238/files/...3007242717367565

SMITHS FALLS, ON, March 7, 2017 http://www.newswire.ca/news-releases/...th-corp-recall-615560563.html

Meiner Meinung nach geht die Aufregung so schnell weg wie sie kam... es scheint mir eher so zu sein, als wenn man in ner Cola Light Zucker gefunden hat XD  

Die beiden gefundenen Artikel passen hier doch sehr gut rein: Gesunde Korrektur, Gewinnmitnahmen oder Panikverkäufe?

Was auch immer der Grund für den heutigen Abverkauf sein mag, es wird kräftig Luft rausgelassen und das nicht zu knapp!


Mehr Infos: http://www.marihuana-aktien.de/news/...ird-kraftig-luft-rausgelassen/

Überblick über Kanadas LP`s (Lizenzierte Produzenten)

Mehr Infos: http://www.marihuana-aktien.de/news/...-lp-s-lizenzierte-produzenten/  

sich auch, wo der Boden ist...

Ich freue mich das es heute was runter gegangen ist, in der Zwischenzeit park ich bei Auscann.. gehört ja quasi zur Canopyfamlie XD

Canopy Growth vows to defend itself in tainted cannabis lawsuit

Shares of Canopy Growth Corp. (WEED.TO) fell in early trading Tuesday as Canada’s largest medical marijuana company vows to defend itself in a class-action lawsuit related to a recent tainted cannabis scare.
Last year, Mettrum Ltd. – a company now owned by Canopy – and Organigram Inc. were found to be selling marijuana that contained the controversial pesticide myclobutanil – a chemical that can lead to serious health problems. Separate lawsuits have been filed against the companies, with both suits asking the courts to refund patient money and pay additional damages.
Canopy was aware of the extent of the problem when it bought Mettrum and will “vigorously defend itself,” the company said in a statement Tuesday.
“Canopy Growth was, and continues to be satisfied with Health Canada's independent decision to classify the Mettrum recall as a Type III recall, defined as ‘a situation in which the use of, or exposure to, a product is not likely to cause any adverse health consequences,’” the company said.
The tainted marijuana scandal resulted in management changes at both companies. Mettrum CEO Michael Haines left after Canopy completed its takeover in January. Organigram announced that Greg Engel will become the company’s new CEO next week as Denis Arsenault, its CEO at the time of the recall, takes on the role of executive chairman.  

TORONTO, March 10, 2017 /CNW/ - S&P Dow Jones Indices Canadian Index Services will make the following changes in the S&P/TSX Canadian Indices effective at the open on Monday, March 20, 2017:

In anticipation of the closing on March 17, 2017, of the acquisition of Manitoba Telecom Services Inc. (TSX:MBT) by BCE Inc. (TSX:BCE), Manitoba Telecom will be removed from the S&P/TSX Composite, Capped Composite and Composite Equal Weight, the S&P/TSX Completion, the S&P/TSX Capped Telecommunication Services, the S&P/TSX Composite Buyback and the S&P/TSX Composite Shareholder Yield Indices effective at the open of trading on Monday, March 20, 2017. The index shares of BCE Inc. will increase at the same time to reflect the issuance of shares as part of the transaction.

Changes to the S&P/TSX Composite Index will also affect the S&P/TSX Completion, Capped Composite and Equal Weight Composite Indices.  Stocks added to or removed from the S&P/TSX Composite Index will also be added to or removed from the appropriate Global Industry Classification Standard (GICS) sector index.  

Canopy Growth to Participate in Bank of America Merrill Lynch 2017 Consumer & Retail Technology Conference

SMITHS FALLS, ON, March 8, 2017 /CNW/ - Canopy Growth Corporation (TSX: WEED) ("Canopy Growth" or "the Company") announced that the Company will participate in the Bank of America Merrill Lynch 2017 Consumer & Retail Technology Conference being held on March 14 – 15, 2017 at the Lotte New York Palace Hotel, New York, NY.  

Canopy Growth's Senior Vice President & Chief Financial Officer, Tim Saunders, will participate on a panel entitled "Marijuana Industry: perceptions are changing, and with them opportunities for growth" which is taking place on Wednesday, March 15, 2017 at 10:30 am.

About Canopy Growth Corporation
Canopy Growth is a world-leading diversified cannabis company, offering diverse brands and curated cannabis strain varieties in dried and oil extract forms.  Through its wholly‑owned subsidiaries, Canopy Growth operates numerous state-of-the-art production facilities with over half a million square feet of indoor and greenhouse production capacity.  Canopy Growth has established partnerships with leading sector names in Canada and abroad.  For more information visit www.canopygrowth.com.

Notice Regarding Forward Looking Statements
This news release contains forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canopy Growth Corporation and its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and Canopy Growth Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.  

Canopy Growth Added to S&P/TSX Composite Index/
Funds That Track The Core Index Will Now Be Buying WEED (A140QA)...  

SMITHS FALLS, ON, March 10, 2017 /CNW/ - Canopy Growth Corporation (TSX: WEED) ("Canopy Growth" or "the Company") today announced that by being added to the S&P/TSX Composite Index, it has achieved another major "first" in the cannabis industry. Management expects this to drive liquidity and increase the percentage of institutions holding Canopy Growth positions. In short, more investors than ever will be buying and holding WEED.

"Being added to the index is an important accomplishment and a reflection of the work we've done to put Canopy Growth top of mind in the investment community," said Bruce Linton, Chairman & CEO. "With international operations, high profile partnerships, and expansion plans all developing rapidly, being included in the index acts as another layer of credibility investors can point to."

The Company was added to the S&P/TSX Composite Index following a quarterly review by S&P Dow Jones Indices. The change will be effective after the close of trading on Friday, March 17, 2017.  

To be eligible for inclusion on the S&P/TSX Composite Index, securities must meet certain market capitalization, liquidity and domicile requirements. In addition, securities must be listed on the Toronto Stock Exchange for at least six full calendar months as of the month-end prior to the applicable quarterly review. For more information on the S&P/TSX Composite Index, please visit  

CANOPY GROWTH COMPLETES $24.25 MILLION PRIVATE PLACEMENT FINANCING Not for distribution to United States newswire services or for dissemination in

... (automatisch gekürzt) ...



 

Canopy Growth announces 50% increase in flower production space and tripling of fulfilment capacity at Tweed Smiths Falls campus

SMITHS FALLS, ON, March 23, 2017 /CNW/ - Tweed Inc. ("Tweed"), a wholly-owned subsidiary of Canopy Growth Corporation (TSX: WEED) ("Canopy Growth" or "the Company"), is pleased to announce the licensing of additional facilities at its flagship Smiths Falls campus, including new grow rooms that will increase flowering space by 50 percent.
"This phase of construction evolves our design and comes in on time and on budget. We've found operational efficiencies that we believe make our existing and newly licensed rooms materially more efficient than they were two years ago. This means more products to market and more variety for customers," said Bruce Linton, Chairman & CEO, Canopy Growth.
Tweed has also received licensing approval for a number of additional rooms targeted at value-added production and operational expansion, including several new fulfilment rooms that will triple Tweed's order fulfilment capacity.
"While more growing space is imperative to our ability to meet demand, we also must be able to scale with increasingly more sophisticated processes and facilities to accommodate rapidly accelerating order demand today and into the future," said Linton.
Following the recent purchase of the 470,000 sq. ft. Hershey Drive campus, expansion work is now fully underway to further increase growing space, value-add processing, product formulation and logistics facilities at the Tweed campus.
Here's to future growth (and shipments).  

marijuana will be legal by July 1, 2018


http://www.cbc.ca/news/politics/liberal-legal-marijuana-pot-1.4041902  


The Liberal government will announce legislation next month that will legalize marijuana in Canada by July 1, 2018.

CBC News has learned that the legislation will be announced during the week of April 10 and will broadly follow the recommendation of a federally appointed task force that was chaired by former liberal Justice Minister Anne McLellan.

Bill Blair, the former Toronto police chief who has been stickhandling the marijuana file for the government, briefed the Liberal caucus on the roll-out plan and the legislation during caucus meetings this weekend.Provinces to control sales

The federal government will be in charge of making sure the country's marijuana supply is safe and secure and Ottawa will license producers.

But the provinces will have the right to decide how the marijuana is distributed and sold. Provincial governments will also have the right to set price.

While Ottawa will set a minimum age of 18 to buy marijuana, the provinces will have the option of setting a higher age limit if they wish.

4 plants per household

As for Canadians who want to grow their own marijuana, they will be limited to four plants per household.

Legalizing marijuana was one of the more controversial promises Justin Trudeau made as he campaigned to become prime minister.

Highlights from the federal marijuana task force report
Hold off on homegrown pot, police chiefs urge government
But in their platform the Liberals said it was necessary to "legalize, regulate and restrict access to marijuana" in order to keep drugs "out of the hands of children, and the profits out of the hands of criminals."

The Liberals had promised to introduce legislation by the Spring of 2017. Announcing the legislation the week of April 10 will allow the party to hit that deadline.

Raids raise questions

Trudeau referred again to that rough timetable a few weeks ago when he said the legislation would be introduced before the summer. But at the same time he also warned that it wasn't yet open season for the legal sale of marijuana.

"Until we have a framework to control and regulate marijuana, the current laws apply," Trudeau said in Halifax March 1.

That warning became more concrete a week later, when police in Toronto, Vancouver and other cities carried out raids on marijuana dispensaries and charged several people with possession and trafficking, including noted pot advocates Marc and Jodie Emery.

Trudeau's promise to legalize marijuana was seen as one of the reasons for the Liberals' strong showing among youth voters in the 2015 election.

But at the NDP's leadership debate in Montreal Sunday, which was focused on youth issues, several of the candidates pointed to marijuana legislation as an example of a broken Liberal promise.

"I do not believe Justin Trudeau is going to bring in the legalization of marijuana and as proof that ... we are still seeing, particularly young, Canadians being criminalized by simple possession of marijuana," said B.C. MP Peter Julian.

Federal marijuana legislation to be introduced in spring 2017, Philpott says  

Canopy Growth Online Store to Offer Patients Products Across Entire Portfolio of Brands

Access to multiple cannabis product offerings through single online store to transform market

SMITHS FALLS, ON, March 29, 2017 /CNW/ – Canadian medical cannabis users are about to have a better way to shop for their medicine. Starting in early April, 2017, Tweed’s new online store, Tweed Main Street, will be the go-to place for the over 50,000 Canadians who are registered with Tweed Inc. (“Tweed”), Bedrocan Canada Inc. (“Bedrocan Canada”) and Mettrum Health Corp. (“Mettrum”), three of Canada’s most established cannabis brands.

Canopy Growth Corporation (TSX: WEED) (OTC: TWMJF) (“Canopy Growth” or the “Company”) owns and operates all three companies (along with licensed producers Tweed Farms Inc. and Agripharm Corp.), which are individually licensed to produce and sell cannabis under Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR). Until now, customers have been required to choose a single producer, register with that producer and shop online based on that single producer’s availability. With the introduction of Tweed’s Tweed Main Street store, all our registered customers will now access the full product catalogues of three of the largest and most recognized producers in one convenient online location.

We look at this as a transformative shift in the market. From doctors to patients to virtually every stakeholder in the sector, we have heard continually that variety, reliability and consistency, matched with high quality products and top customer care are essential. Bringing the sector’s three leading producers into a single online marketplace is the most important thing we can do to serve our clients.

With many sector firsts, including the first public listing, the first diversified production platform, the first to introduce CFPC Mainpro accredited CMEs across Canada, the first to legally sell seeds for home-grow production, the first to export Canadian medical marijuana to Germany, and the establishment of Canopy Health Innovations to invest in clinical research, Canopy Growth has been leading the way forward in this exciting sector since day one. It is our privilege to introduce another first: serving tens of thousands of Canadians from a single legal access point, leveraging an unparalleled production platform and unwavering commitment to service, variety and product safety.

Here’s to Future Growth.  

https://www.investing.com/equities/tw-holdings-ltd-financial-summary

POLITICS
Queensland Takes Lead as Australian Cannabis Stocks Soar

JOE WILSON
March 29, 2017

It was a big week for medical cannabis in Australia last week, with Queensland’s Labor government announcing that it will allow licensed cannabis growers in the state to sell cannabis seeds to other growers and manufacturers.

Minister for Agriculture and Fisheries Bill Byrne made the announcement on Friday afternoon, after changes were made to the state’s drug laws earlier in the week.
Australia’s move to legalize and regulate medical cannabis last year took many by surprise, and many local officials are still playing catch-up. But in Queensland, the state government has been championing the economic benefits of a robust cannabis industry. Allowing the sale of seeds is aimed at giving growers access to the nascent market allowing licensed growers a chance to fully realise the economic value of their cultivation rights.
“This creates new opportunities for Queenslanders,” said Byrne, the agriculture minister, adding that the policy should benefit industry players big and small.

RELATED STORY
What Will Australian Import Changes Mean for Local Cannabis Growers?
“The changes will be mutually beneficial for licensed industrial cannabis growers and those Queensland businesses interested in being part of the emerging medicinal cannabis industry in Australia,” he added.
Queensland Minister for Health Cameron Dick has also taken a leading role, negotiating a $6 million investment in medical cannabis research with GW Pharmaceuticals. And the state was the first to create and release medical guidance documents for doctors seeking to prescribe medical cannabis.
Queensland’s example suggests there’s a path that can both ensure access for patients and reap economic benefits.
The scheme currently permits the prescription of a limited range of pharmaceutical products only for certain conditions, such as drug-resistant epilepsy in children, multiple sclerosis, chemotherapy-induced nausea, and symptom control in palliative care. The guidance is based on scientific reviews, and keeps the medical profession up to date with the latest clinical trials.
Queensland is also pushing for the rest of Australia to get on board. In February, Health Minister Dick called on the federal government to add medical cannabis to the Pharmaceutical Benefits Scheme (PBS)—meaning a federal government subsidy for medical cannabis. Such a move would make cannabis substantially more affordable for patients in need.
Although the federal government rejected the proposal, officials have taken other steps toward reform. Federal importation rules have been relaxed, and the market is responding with relentless optimism. Cannabis stocks in the Australian market have gone up by a staggering 130% this year on average, according to Bloomberg. By comparison, the S&P/ASX 200, an Australian Securities Exchange index, has gained less than 1%.

RELATED STORY
Australia Loosens Cannabis Import Rules to Speed Patient Access
Huge gains were made by cannabis growers such as AusCann (ASX:AC8), which was granted the first commercial licence to cultivate medical cannabis in Australia. And even peripheral businesses—from shovels and picks to hydroponics—are getting in on the boom. One such manufactuer, The Hydroponics Co., will go public on the ASX in April under the cheeky ticker symbol THC. The $8 million initial public offering is reportedly three times oversubscribed.
The booming cannabis industry is creating new economic incentives—and pressures—for state governments in Australia. Queensland’s example suggests there’s a path that can both ensure access for patients and reap economic benefits for the region. However, it also makes clear that local officials need to coordinate with the federal government to prevent a patchwork of regulations from hamstringing the young industry.